Navigation Links
Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Date:10/28/2009

EXTON, Pa., Oct. 28 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody that targets a tumor-associated antigen over-expressed in many solid tumors.

Under the terms of the agreement, Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Financial terms were not disclosed. Preclinical studies, conducted by Centocor Ortho Biotech, have shown that the relevant antigen is over-expressed in many solid tumors.

"We are delighted to conclude this license agreement with Centocor Ortho Biotech as we are committed to bringing healthcare solutions to cancer patients, especially for areas of unmet medical need," said Philip Sass, Ph.D., Chief Operating Officer of Morphotek. "Morphotek is well positioned to apply its technologies, knowledge and expertise in monoclonal antibody development for the development and commercialization of this antibody. The preclinical data package for this antibody have shown anti-cancer effects and we look forward to validating these in human trials."

About Morphotek

Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. The technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

Eisai Inc.

Eisai Inc. is a wholly-owned subsidiary of Eisai Corporation of North America. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), the company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully-integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities in Massachusetts, New Jersey and North Carolina, as well as manufacturing facilities in Maryland and North Carolina. For more information about Eisai, please visit www.eisai.com.

*On October 1, 2009, Eisai Research Institute of Boston, Inc. (established in 1987) and Eisai Medical Research Inc. (established in 2002) were merged into Eisai Inc.

SOURCE Morphotek(R), Inc.


'/>"/>
SOURCE Morphotek(R), Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors
2. Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
3. Connectyx Announces the MedFlash Personal Health Manager
4. Allegheny Medical Announces Launch of the New AlleghenyMedical.com
5. Zix Corporation Hits High End of Financial Guidance as Company Announces Third Quarter 2009 Financial Results
6. 1-800-Therapist Announces New Executive Team and Tele-Therapy Offering
7. Ziosoft Announces Agreement with Imaging & Medical Information Technology to Distribute Ziosoft's 3D Advanced Visualization Software in Turkey
8. Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice President, Business Development
9. CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change
10. Spain-United States Chamber of Commerce Announces 30th Annual Gala Honoring IBT Group at The Biltmore Hotel - November 6
11. Akorn, Inc. Announces Third Quarter 2009 Earnings Release and Conference Call Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... , ... April 27, 2017 , ... ... natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used the same ... that actually works! , Countless deodorants flood the aisles that contain harmful chemicals ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise ... area this year. , The first new location will open at the corner ... at 84th and Northern Lights Drive this fall. And the third location is in ...
(Date:4/26/2017)... MN (PRWEB) , ... April 26, 2017 , ... ... that improve supply management in hospitals, today announced it has completed a round ... Black Granite Capital LLC and its partners. Black Granite Capital is a growth ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... that describes the adoption of e-prescribing as measured in Part D Medicare data. ... deliver prescriptions to pharmacies, either using e-prescribing, faxes or paper. The PaPR ...
(Date:4/26/2017)... ... , ... Infertility may be a result of an underlying ... women become pregnant upon treating their diagnosis. , To properly diagnose ... We can provide the necessary information to diagnose and treat your problem. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology: